BULEVIRTIDE WITH OR WITHOUT PEGIFN? FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES

Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, displaying a superior risk of cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC). Pegylated-Interferon ? (pegIFN?), the only off-label therapeutic option that has been available for the last 30 years, has suboptimal response rates and it is poorly tolerated. Among the new treatment strategies under clinical evaluation, the entry inhibitor bulevirtide (BLV) is the only that received conditional approval from the European Medicines Agency (EMA) in July 2020, at the dose of 2mg daily, for the treatment of adult patients with compensated CHD.